Vivity complements Alcon’s existing IOL portfolio by providing an additional option for cataract patients to treat presbyopia A first-of-its-kind, non-diffractive lens that offers a continuous ...
GENEVA--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, has commercially launched the first and only non-diffractive extended depth ...
GENEVA, March 25, 2025--(BUSINESS WIRE)--Regulatory News: Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that Vivity ®, the most ...
TORONTO, Nov. 17, 2020 /CNW/ - Alcon, the global leader in eye care, is pleased to announce the Canadian launch of AcrySof ® IQ Vivity ®, a first-of-its-kind, surgical lens designed to help cataract ...
Alcon ALC recently announced that its Clareon Vivity intraocular lens (IOL), featuring extended depth of focus (EDOF) technology, has received CE Mark approval. The lens, made from Alcon's advanced ...
VIENNA — In this Healio Video Perspective from the ESCRS meeting, Nic Reus, MD, presents the results of a real-world evidence study assessing the outcomes of the Vivity extended depth of focus IOL ...
These results and additional data are being discussed in 11 sessions with world-renowned surgeons at the 41 st Congress of the European Society of Cataract and Refractive Surgeons (ESCRS), currently ...
GENEVA--(BUSINESS WIRE)--Alcon (SIX/NYSE:ALC), the global leader in eye care announced AcrySof® IQ Vivity®, a first-of-its-kind intraocular lens (IOL) is now commercially available in select European ...
Alcon Vivity Registry continues to demonstrate excellent outcomes with AcrySof IQ Vivity and AcrySof IQ Vivity Toric, the first and only PCIOL + with wavefront-shaping technology World-renowned ...
Vivity is a first-of-its-kind, non-diffractive extended depth of focus IOL with Alcon’s proprietary non-diffractive X-WAVE™ technology, which stretches and shifts light without ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback